1Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis[J]. Biochem Biophys Res Commun, 1997, 234(1):137-142.
2Simonet W S, Lacey D L, Dunstan C R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density[J]. Cell, 1997, 89(2):309-319.
3Wong B R, Josien R, Lee S Y, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor[J]. J Exp Med, 1997, 186(12):2075-2080.
4Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL[J]. Proc Natl Acad Sci U S A, 1998 , 95(7):3597-3602.
5Lacey D L, Timms E, Tan H L, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation[J]. Cell, 1998, 93(2):165-176.
6Kong Y Y, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand [J]. Nature, 1999, 402(6759):304-309.
7Kong, Y Y, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis[J]. Nature, 1999, 397(6717):315-323.
8Lomaga M A, Yeh W C, Sarosi I, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling[J]. Genes Dev, 1999, 13(8):1015-1024.
9Naito A, Azuma S, Tanaka S, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice[J]. Genes Cells, 1999, 4(6):353-362.
10Hsu H, Lacey D L, Dunstan C R, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand[J]. Proc Natl Acad Sci U S A, 1999, 96(7):3540-3545.
